This AI company scans penis pictures for STIs

A company called HeHealth claims its AI model can detect STIs from a single snapshot. Its unproven tech is in an FDA gray zone.

April 2, 2024 Check out STAT+

Sponsored By

STAT STAT+ | This AI company scans penis pictures for STIs. Its unproven tech is in an FDA gray zone Company called HeHealth claims AI model can detect STIs from a single snapshot. Product is not FDA approved, and not yet proven accurate. By Lizzy Lawrence STAT+ | Roivant CEO: New deals could 'materialize later this year' STAT spoke with Roivant CEO Matt Gline about the company's data, its stock buyback, and the prospect that the company will license even more assets. By Matthew Herper STAT+ | Verve Therapeutics 'pauses' tests of its gene editor for heart disease and prioritizes a backup treatment The company said it has already received approval from Canadian and European regulators to begin a clinical trial of a similar gene-editing compound. By Matthew Herper Alex Hogan STAT STAT+ | Watch: Medicare billing forms are running out of space for growing health care prices Medicare forced to expand its billing system to handle claims up to one penny under $100 million. Analysts call it "mind-boggling," "a sign of the times." By John Wilkerson STAT+ | FDA clears digital stethoscope company's AI algorithm for heart failure An AI algorithm to detect heart failure, embedded in a digital stethoscope, has earned clearance from the Food and Drug Administration. By Lizzy Lawrence STAT+ | The biotech scoreboard for the second quarter: 32 stock-moving events to watch Among other readouts, Sage Therapeutics will report study results on two drugs and Pfizer is expected to announce results from a gene therapy study. By Adam Feuerstein Adobe Opinion: A nation with too few pediatricians could see health care costs soar This year's Match saw the fewest number of graduating medical students wanting to be pediatricians since 1994. That's a problem. By Sallie Permar and Robert J. Vinci STAT+ | Gritstone Bio says personalized cancer vaccine falls short in key trial The company said it plans to launch a Phase 3 study in 2025, but that will likely be dependent on having adequate funds. By Jason Mast

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Daily Recap? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2024, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser